Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases.
$1.65+2.17%
报价 2026-11-13
市值
$320.1M
EV
$295.5M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -73.4%
$1.61$6.18
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-13不在筛选范围:industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ALTAltimmune, Inc. | $320.1M | +2.2% | -100.0% | -36,387.8% | – | – | – | |
| LBRXLB Pharmaceuticals Inc Common Stock | $1.39B | +1.3% | – | 0% | – | – | – | |
| ANROAlto Neuroscience, Inc. | $1.18B | -3.5% | – | 0% | – | – | – | |
| AURAAura Biosciences, Inc. | $740M | -6.6% | +2.7% | 0% | – | – | – | |
| ANNXAnnexon, Inc. | $642.3M | -1.3% | -77.8% | 0% | – | – | – | |
| LRMRLarimar Therapeutics, Inc. | $313.7M | +11.9% | – | 0% | – | – | – | |
| DBVTDBV Technologies S.A. | $263.5M | -3.6% | – | -110.7% | – | – | – | |
| AMRNAmarin Corporation plc | $235.4M | -2.5% | – | 65.7% | – | – | – | |
| ACIUAC Immune S.A. | $216.8M | -0.5% | – | 100% | – | – | – | |
| 同行中位数 | – | – | -37.6% | 0% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。